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Abstract
Background: Adenomyoepithelioma (AME) of the breast is a rare tumour of unpredictable clinical behaviour. Most
of the tumours are benign with some giving local recurrences or distant metastases.
Case Presentation: We report a case of late lung metastases in a woman with a history of breast
adenomyoepithelioma. Partial lobectomy was performed for lung lesions and initial diagnosis was epithelial-
myoepithelial carcinoma.
Conclusion: Careful slide’s revision of both breast and pulmonary lesions showed identical microscopic appearance
with lung tumour performing more malignant features. Tumour cells in both: breast and pulmonary lesions were
positive for cytokeratin and EMA (epithelial cells) and also for SMA, S100 and vimentin (myoepithelial cells).
Two years and 7 months follow-up showed no recurrent neoplastic disease in our patient.
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Background
Adenomyoepithelioma (AME) is a tumour characterized
by a bicellular proliferation consisting of glands with an
inner epithelial and an outer myoepithelial cell layer.
The classification of the World Health Organization [1]
divides the adenomyoepithelioma into a benign type
where both the epithelial and myoepithelial component
are histologically non-malignant and a form, which shows
a malignant transformation [2].
Adenomyoepithelioma can be found in salivary gland,
skin adnexal, lung and this tumor may develop in breast
[2–5]. It is generally considered to be benign or to show
a low-grade malignancy. For the first time this tumour
was reported in the breast by Hamperl in 1970 [6, 7]. The
biological behavior of tumours developing in mammary
glands may range from benign to malignant transform-
ation of either epithelial or myoepithelial component
separately or both [2, 7, 8]. The age of patients with breast
adenomyoepithelioma ranges from 26 to 82 years, with an
average of around 60 years [9]. These lesions develop
usually as single foci with possible infiltration of sur-
rounding breast tissue [8]. Foci of calcification may be
seen on ultrasound examination. These cases that ex-
hibit aspects of malignant transformation are rare in
the literature. The myoepithelial cells express cytokera-
tins of the basal layer of stratified epithelia (CK5, CK14,
and CK17), α-smooth muscle actin (SMA) and the heavy
chain-myosin (hc-myosin). Some tumor suppressor pro-
teins, including p63, p73, 14-3-3 sigma, maspin and
Wilms Tumor (WT-1) have been preferentially detected
in myoepithelial cells [2]. Morphological features of malig-
nancy that could predict the potential for local recurrence
and/or metastasis are not well-established. Cellular pleo-
morphism, mitoses, necrosis, invasion of the surrounding
tissue and association with other types of malignant tu-
mors such as invasive ductal carcinoma and undifferenti-
ated carcinoma are thought to be the most important [10].
Epithelial-myoepithelial carcinoma occurs most frequently
in both major and minor salivary glands, where accounts for
approximately 1 % of primary neoplasms. It belongs to low-
grade tumours that may locally recur and less frequently
metastasise. Other known locations for these tumours are
skin and breast [11]. Primary epithelial-myoepithelial carcin-
oma of lung has only recently been described [12–15].
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Myoepithelial cells are believed to play an important role in
the development of this type of tumours. Subcellular aber-
rant location of p27/kip-1 seems to be crucial in loss of
growth-inhibition function and uncontrolled proliferation of
myoepithelial cells [11]. In most of these tumours no aggres-
sive clinical course has been noted, though in the recently
described cases the follow-up time has been too short for
the assessment of their clinical behaviour.
The aim of the study is to present a case of late pulmon-
ary metastases of breast adenomyoepithelioma in 57 years
old woman.
Case Presentation
Fifty six years old woman had a history of breast tumour
and had left-side mastectomy in 2007. The control chest
radiograph and computed tomography (CT) scan per-
formed in 2012 revealed two nodular masses located in
her right lower (measuring 26x31mm) and middle lobe
(diameter 96 mm) (Fig. 1a). No associated enlarged lymph
nodes were found. The patient had no history of smoking
or pulmonary infectious disease. She underwent positron
emission tomography-computed tomography (PET-CT)
scan that showed low-grade uptake with an SUV of max
6,2 after 120 min within both pulmonary lesions. There
was no uptake within other parts of the body, including
breast and salivary glands. Therefore, a pulmonary lower
and middle sleeve lobectomy was performed and the ma-
terial was obtained for histopathological examination.
Material and methods
Formalin fixed and paraffin-embedded sections were
stained with hematoxylin and eosin (H + E) and Periodic
acid Schiff (PAS). Additional sections were stained with
panel of antibodies listen in Table 1. A commercially
available detection kit (Dako Envision Plus-HRP, DAKO,
Glostrup, Denmark) was used according to the manufac-
ture’s instruction. Slides were lightly counterstained with
1 % Harris’ hematoxylin.
As breast lesion was diagnosed in different laboratory
(in 2007), we have asked for and reviewed the slides and
immunohistochemical stainings. The lesion at that time
was diagnosed as adenomyoepithelioma and two separ-
ate laboratories confirmed the diagnosis. We have made
the revision of breast tumour slides as well as immuno-
histochemical stainings.
Results
Gross examination of the right lung lower lobe revealed a
circumscribed, nonencapsulated nodular mass measuring
Fig. 1 Lung tumour: Metastatic adenomyoepithelioma with component of epithelial-myoepithelial carcinoma. a PET-CT scan: Two nodular masses
located in right lower (measuring 26x31mm) and middle lobe (diameter 96 mm). b Light microscope. Inner layer of glandular structures lined by
epithelial cells, outer layer formed by myoepithelial cells with clear cytoplasm, mild nuclear atypia and some nucleoli visible. Homogenous, hyalinised
stroma. H + E x400. c Immunochistochemical staining for cytokeratin positive in epithelial cells. x400. d Immunochistochemical staining for SMA positive
in myoepithelial cells. x400
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35x30x30mm infiltrating focally the bronchial wall (the
bronchus intermedius). The cross section was uniform
and grey with punctate foci of necrosis. Examination of
middle lobe revealed well circumscribed nodule measu-
ring 10x7mm located close to the bronchial wall, with no
infiltration nor necrosis grossly visible.
Microscopic examination of revealed in both lesions
unencapsulated, polypoid epithelial neoplasms that infil-
trated focally the bronchial wall and pulmonary paren-
chyma. The tumour mass was composed of two types of
cells that formed glandular or duct-like pattern (Fig. 1b).
The inner (luminal) layer of cells had eosinophilic cyto-
plasm and centrally located uniform nuclei without nu-
cleoli. Large polygonal cells with clear cytoplasm and
uniform nuclei formed the outer layer (Fig. 1b). The
duct-like structures contained PAS positive material in
the luminal spaces. The stroma had hyalinised and eosino-
philic appearance (Fig. 1b). Mitotic figures were present
(<5 mitotic figures/10 high power fields-HPF). Immuno-
histochemical studies confirmed the biphasic nature of the
tumour (Fig. 1c, d). Results are summarized in Table 1.
There were microscopic focal necrosis, nuclear atypia and
signs of the adjacent pulmonary parenchyma infiltration.
No lymphovascular space invasion was noticed. The initial
diagnosis was epithelial-myoepithelial carcinoma.
Gross description that we found in the diagnosis while
revising microscopic slides of the breast lesions revealed
the information about two separate firm, well demarcated
lesions within the left breast measuring: 26x18x16mm and
22x20x18mm respectively. Microscopic appearance of
revised slides was consistent with the diagnosis of ade-
nomyoepithelioma (Fig. 2a, b). However single mitotic fig-
ures were present (Fig. 2b) Immunohistochemical study
showed identical immunohistochemical profile with above
presented lung lesion (Table 1, Fig. 2c, d). The hormone
estrogen and progesterone receptors were negative in
both: breast and lung tumours.
Discussion
Adenomyoepithelioma of the breast is a rare disorder
characterized by the simultaneous proliferation of ductal
epithelium and myoepithelial cells. In 1991, Tavassoli [9]
classified these tumours according to their malignant
potential and subdivided them into benign and malig-
nant lesions in which one of/or both components can
perform malignant features. In 2003, this classification
was adopted by WHO. The average age of onset is around
60 years [3, 9, 16] (our patient was at 50 years when breast
tumour was diagnosed). Patients usually present a soli-
tary, well-circumscribed, sometimes palpable nodule
(depending on location and size), measuring on average
20–50 mm [3, 17].
No risk factors are reported for this type of tumours
[16, 18]. The mammographic and sonographic signs are
not specific; however they can guide the diagnosis and
give a precise assessment of the lesions [16]. The surgi-
cal removal is the treatment of choice for both benign
and malignant tumours [3, 17]. Local recurrence has
been described and is more common if the margin of ex-
cision is narrow or there is incomplete excision [3].
Microscopic examination reveals formation of papillary
or micropapillary, tubular, cystic or solid areas formed by
neoplastic cells. Single tumour may represent a mixture of
these components, or one of the components may replace
most of tumour mass [3, 16–19]. In some cases the solid
areas were prominent [3, 4, 17]. PAS positive, diastase-
sensitive amorphous material is seen within the tubular
lumina or intercellular spaces. In some cases the stroma is
hyalinised or shows myxoid change. In some cases focal
atypia, necrosis, and presence of mitotic figures were re-
ported and are usually associated with cases that either
recurred or had a malignant clinical outcome [3, 4, 17, 20].
The review of breast tumour slides in our case re-
vealed mostly tubular microscopic appearance with hya-
linised stroma. Single mitotic figures and focal mild
nuclear atypia were present (Fig. 2a, b).
The cytoplasm of epithelial cells of AME uniformly
reacts with antibodies to cytokeratins, such as cytoker-
atin AE1/3 (CAM 5.2, or CK7.6, 7) [2–4, 18]. The
luminal surfaces of the glandular cells are positive for
the epithelial membrane antigen. The myoepithelial
component reacts with p63, smooth muscle myosin
(SMA) heavy chains, CK5, CD10, calponin, actin, and
S100 [2, 3, 7, 16, 18]. Proliferative index of Ki-67
immunostaining is present in both compartments of
the tumor but may be higher in the myoepithelial cells
than it is in the ductal cells [3, 17, 21]. Immunostaining
for estrogen is either negative or weakly positive in a
Table 1 Reagents used in immunohistochemical characterization
for breast and pulmonary lesions






1:100 DAKO positive negative
S-100 protein 1:3000 DAKO negative positive
Smooth
muscle actin
1:50 DAKO negative positive
p63 protein 1:100 ZECA Corp negative negative
TTF-1 1:50 DAKO negative negative
Ki-67 antigena 1:50 DAKO Positive positive
EMA 1:50 DAKO Positive negative
Vimentin 1:50 DAKO negative positive
PR 1:50 DAKO negative negative
ER 1:50 DAKO negative negative
aKi-67 positive in 4,5 % of tumour cells (epithelial and myoepithelial cells) in
pulmonary lesions. Not performed on breast tumour
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patchy pattern. Progesterone receptor and ERBB2
(formerly Her2/neu) have, however, been consistently
reported to be negative in all the published studies
[3, 22].
Immunohistochemical results of the breast lesion diag-
nosed in our patient are consistent with desribed above
and presented in Table 1.
Differential diagnosis should include intraductal papil-
loma, intraductal hyperplasia, ductal carcinoma or nipple
adenoma. A diagnosis of AME is favored if myoepithelial
proliferation is extensive and involves the lesion diffusely
[3, 5, 18]. In nipple adenoma presence of florid ductal
hyperplasia and the pseudoinfiltrative pattern without
fibrous hyalinised stroma are helpfull features for differen-
tation. Other tumours that should be included in the dif-
ferential diagnosis are: fibroadenoma, phyllodes tumor or
tubular adenoma with AME-like areas, ductal adenoma,
and nodular adenosis, clear cell carcinoma, microglandu-
lar adenosis [3, 5, 18]. Microglandular adenosis is charac-
terized by an absence of myoepithelial layer and S100
positivity [18].
The prognosis of benign and locally recurrent disease
is good [3, 5, 17]. Chemotherapy has been used in few
malignant cases without much success, however eribulin
was recently presented by Lee et al. [5] to have a benefit
effect on breast AME that presented distant metastases.
Metastases to axillary lymph nodes may be reported
[2–4, 17, 23]. Several cases with distant metastases have
been reported, mainly to lungs [2, 5, 17], brain, thyroid,
chest wall or even abdominal cavity [5, 23]. The prog-
nosis of metastatic malignant adenomyoepithelioma is
poor [5]. Epithelial-myoepithelial carcinoma (EMC), also
reported in the breast, is extremely rare tumour in this
location performing prominent malignant microscopic
features such us: more solid structure, nuclear pleo-
morphism, high mitotic activity, areas of necrosis and
infiltration of surrounding structures [21]. Moushine et al.
[16] and Shah et al. [24] presented cases of EMC with
described above malignant histologic features, arising in
breast adenomyoepithelioma.
Our case presents a patient with lung tumours develo-
ping 5 years after breast adenomyoepithelioma. Micro-
scopic appearance of lesions located in breast and lung
was similar with lung tumours performing more malig-
nant appearance: nuclear pleomorphism, mitotic figures,
and focal necrosis. Immunohistochemical profile was
identical in both: breast and lung tumours and is sum-
marized in Table 1.
Fig. 2 Breast tumour: Adenomyoepithelioma. a, b Light microscope. Inner layer of glandular structures lined by epithelial cells, outer layer
formed by myoepithelial cells with clear cytoplasm, mild nuclear atypia and single mitotic figures. Homogenous, hyalinised stroma. H + E x400.
c Immunochistochemical staining for SMA positive in myoepithelial cells. x400. d Immunochistochemical staining for cytokeratin positive in
epithelial cells. x400
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Such late presentation of metastases is unusual for the
breast lesions of AMEs group. Nadelman [25] presented
two cases with lung metastatic disease that were diag-
nosed at the same time and one year after breast tumour
was diagnosed. Maffini [26] presented a case of malig-
nant breast AME with lung metastasis one year later
and Lee [5] reported metastatic lung tumour 10 months
after the initial diagnosis of breast AME.
Primary pulmonary neoplasms showing a mixture of
epithelial and myoepithelial elements are extremely infre-
quent with only 25 cases published, classified as “adeno-
myoepithelioma”, “pneumocytic adenomyoepithelioma”,
“myoepithelioma” and epithelial-myoepithelial carcino-
ma”. The last known case about pulmonary neoplasm
with biphasic morphology was published by Arif et in
2012 [27]. Epithelial-myopepithelial carcinoma is an
uncommon, low-grade malignant salivary gland neo-
plasm characterized by neoplastic proliferation of epi-
thelial and myoepithelial cells. Neoplasms with similar
morphology have been reported in the breast, skin and
lacrimal glands. This rare tumour has only been diag-
nosed in last two decades [11, 15, 28]. According to
WHO this tumour is treated as malignant neoplasm
composed of variable proportions of two types of cells,
which typically form gland-like structures. The biphasic
morphology is represented by an inner epithelial cells layer,
enveloped by an outer layer of clear myoepithelial cells.
Pulmonary epithelial-myoepithelial carcinoma appears
mainly in middle-aged patients (34–76 age range) with
slight female predominance [11, 27]. The youngest re-
ported patient was 7 years old boy [29]. Symptoms varied
from asymptomatic cases to cough, hemoptysis, thoracic
pain, fever, dyspnoea, pneumonia or recurrent infections
[11, 30, 31]. The size of the tumour ranges from 0,8 to
16 cm (average 3,2 cm). Grossly, most of these neoplasms
arise as well-defined, endobronchial, nonencapsulated
polypoid mass [11]. In most described cases a connection
to the wall of a bronchus was evident, less commonly the
tumour presented as intraparenchymatous mass without
apparent bronchial connection [32].
Immunohistochemically the inner epithelial cells layer
shows positivity for EMA and cytokeratins: low-molecular
weight but is negative for S-100 protein, vimentin and
smooth muscle actin (SMA). The opposite reaction is
present in outer myoepithelial cells layer; they are negative
for EMA and cytokeratins but positive for S-100 protein,
SMA and weekly for vimentin. Immunopositivity for cal-
ponin, CD117 and GFAP was reported in these cells [27].
These cells show positivity for p63, which is known as a
marker of squamous epithelium. P63 positivity is re-
stricted to basal cells of respiratory epithelium and
peripheral cells of bronchial mucous glands that are be-
lieved to be the counterparts of myoepithelial cells.
These observations suggest that p63 might be one of
the markers of myoepithelial cells [30]. Ki-67 labeling is
reported in few cases and it ranges from < 1 % to < 2 %.
Microscopic appearance of both lung tumours in our
patient was consistent with above described pulmonary
EMC. Pathologist, at the time of the diagnosis, was not
aware of the type of primary breast lesion. The immuno-
profile in both lesions was consistent with other cases of
pulmonary epithelial-myoepithelial carcinoma reported,
results are summarized in Table 1. Ki-67 was positive
in approximately 4,5 % of tumour cells (epithelial and
myoepithelial). TTF-1 was negative in both: epithelial
and myoepithelial cells.
As the breast tumour in our patients that occurred
5 years prior to lung lesions have been diagnosed as adeno-
myoepithelioma, after the careful revision of breast tumour
slides and patients history, we conclude that the lung
tumours diagnosed as epithelial-myoepithelial carcinoma
should be treated as late metastases of the breast malignant
adenomyoepithelioma with metastatic tumour being more
malignant. Presence of mitotic figures, signs of nuclear aty-
pia, focal infiltration of pulmonary parenchyma as well as
focal necrosis should be treated as component of epithelial-
myoepithelial carcinoma. Similar microscopic appearance
with primary breast tumour, identical immunohistochemi-
cal profile and two foci located within the same lung
support metastatic rather that primary origin of pulmonary
lesions. Several authors conclude that breast AMEs per-
forming as tumours over 2 cm should be treated as poten-
tially malignant [3, 5, 7, 8, 17]. Two primary breast lesions
in our case were over 2 cm each. Histology of these tu-
mours presented potential features of malignant behaviour
(single mitotic figures, signs of nuclear atypia). However,
for the best of our knowledge, such late presentation of dis-
tant metastases of breast AME as in our patient has never
been reported before, and this makes the case unique.
Conclusion
We conclude that atypical features should be noted in
the pathology report of breast adenomyoepithelioma and
careful follow-up should be employed, due to the lack
of experience with these tumours, complete excision
with adequate margins is recommended to decrease the
potential for recurrence and metastasis. Precise criteria
for microscopic diagnosis (benign versus malignant) as well
as optimal treatment strategies remain to be determined.
The patient has not performed the further metastases
since the lobectomy was done; she stays under the care-
ful clinical and radiologic follow-up.
Consent
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